Ben-Shlomo S, Zvibel I, Rabinowich L, Goldiner I, Shlomai A, Santo EM, et al
Nonetheless, future GLP-1RA that demonstrated reduced incidence of nausea and vomiting will have a significant competitive advantage in the market
Efectos gastrointestinales severos : Nuseas, vmitos o diarrea persistentes que no mejoran despus de las primeras semanas pueden requerir ajuste de dosis o cambio de medicamento
With obesity affecting more than a third of adults in the state and contributing to serious, preventable health conditions, accessible, effective treatment is more important than ever
Even though office-based treatments are highly effective and major complications are uncommon, recurrence rates can be high, requiring patients to undergo additional treatments